Fused tricyclic compounds as serine-threonine protein kinase and PARP modulators
US7956064B2 · kind B2 · utility
20Cited by
1References
14Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Aug 31, 2007 |
| Grant date | Jun 7, 2011 |
| Priority date | — |
| Expiry date | Oct 5, 2029 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07D513/04
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The invention relates in part to fused tricyclic compounds having certain biological activities that include, but are not limited to, inhibiting cell proliferation, modulating protein kinase activity and modulating polymerase activity. The fused tricyclic compounds of the invention can modulate casein kinase (CK) activity and/or poly(ADP-ribose)polymerase (PARP) activity. The invention also relates in part to methods for using such fused tricyclic compounds.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.